Bristol Myers Squibb's Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results Pharmaceutical Investing
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study Pharmaceutical Investing
VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision , is Now Available Pharmaceutical Investing
BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium® Biotech Investing
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS for the Treatment of Adults With Active Lupus Nephritis Pharmaceutical Investing
Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2 Company News
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2 Company News
BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant Cannabis Investing News
Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference Company News
Upadacitinib Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease Pharmaceutical Investing
